A compounded, veterinarian-prescribed treatment for Feline Infectious Peritonitis (FIP) is now available in both the United States and Canada, the American Animal Hospital Association (AAHA) announced this week.
FIP, long considered a universally fatal disease in cats, has seen a shift in prognosis with the development of this treatment. Previously, a diagnosis of FIP meant a grim outlook for pet owners. The new treatment utilizes antiviral medication, specifically remdesivir, compounded for feline utilize. The availability of this compounded formulation represents a significant step forward in veterinary medicine, offering a potential lifeline for cats afflicted with the disease.
The treatment’s emergence follows research indicating the effectiveness of antiviral therapies against FIP. According to reporting from Catster, the development offers “new hope for a fatal feline disease.” The medication targets the virus that causes FIP, offering a chance for recovery where previously there was none.
FIP manifests in two primary forms: “wet” FIP, characterized by fluid accumulation in the abdomen or chest, and “dry” FIP, which presents with a wider range of non-specific symptoms like fever, weight loss, and neurological issues. PetMD reports that early diagnosis is crucial, but can be challenging due to the varied presentation of the disease. The new treatment is applicable to both forms of FIP, though treatment protocols may vary depending on the specific case.
The availability of the compounded treatment does not signify a complete eradication of FIP’s challenges. The treatment requires a veterinarian’s prescription and is compounded specifically for each patient, meaning We see not a readily available, off-the-shelf medication. The cost of treatment can be substantial, presenting a financial barrier for some pet owners.
Recent research, as highlighted by Genetic Engineering and Biotechnology News, suggests that cell therapy in cats is also shedding clues relevant to understanding and potentially treating Long COVID in humans. While distinct from the FIP treatment, this research underscores the growing role of feline health in broader medical advancements.
As of February 16, 2026, the AAHA has confirmed the treatment’s availability, but further details regarding long-term efficacy and potential side effects are still being gathered. Veterinary specialists continue to monitor cases and refine treatment protocols.
